Image Credit: Anirudh
Scientific Frontline: Extended "At a Glance" Summary: Genetic Risk Factors of Fibromyalgia
The Core Concept: Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, and cognitive difficulties, which a landmark study has now definitively linked to specific biological and genetic variations. Researchers identified 26 distinct genomic regions associated with the condition, proving that it stems from neurobiological differences rather than purely psychological origins.
Key Distinction/Mechanism: Rather than being an isolated musculoskeletal or psychological issue, fibromyalgia manifests through genetic variants that alter brain and nerve function, specifically affecting how the central nervous system processes pain.
Major Frameworks/Components:
- Genomic Variants: Researchers identified 26 specific regions within the human genome that actively influence the risk of developing fibromyalgia.
- The HTT Gene Connection: The most significant genetic variant discovered is located within the HTT gene, which is notably responsible for Huntington's disease when mutated.
- GPR52 Receptor Regulation: A prominent variant involves the GPR52 receptor, which regulates HTT levels and is actively being researched as a neurodegenerative drug target.
- Symptom Clustering: The research highlights a shared genetic architecture between fibromyalgia and other conditions, such as irritable bowel syndrome, post-traumatic stress disorder, and lower back pain, indicating common neural pathways.
- Environmental Triggers: The genetic variants alone are likely insufficient to cause the syndrome; they act in concert with external triggers, such as painful arthritic conditions, environmental exposures, or life events.
Branch of Science: Genomic Epidemiology, Molecular Genetics, and Neuroscience.
Future Application: The discovery of shared biological pathways may allow existing pharmaceutical research—particularly drugs targeting the GPR52 receptor for Huntington's disease—to be repurposed for treating fibromyalgia and other clustered chronic pain syndromes.
Why It Matters: This research definitively legitimizes fibromyalgia as a condition with a clear biological and genetic foundation, transforming how the medical community understands, categorizes, and ultimately treats chronic pain disorders globally.
The landmark study, which involved scientists at King’s College London and was published in Nature Medicine, highlights how the nervous system plays an important role in the development of the disorder.
Fibromyalgia is characterized by widespread pain and tenderness, fatigue, and problems with sleep, memory, and mood. Despite affecting about 2 percent of the global population, its biological causes have remained unclear. The results of this study are an important step toward resolving that uncertainty.
The team analyzed genetic data from more than 2.5 million adults, of whom 55,000 had been diagnosed with fibromyalgia. The researchers scanned millions of genetic differences across the DNA of people with and without fibromyalgia to find changes that were more common in those with the condition. This enabled them to identify DNA sequence variants in 26 regions of the genome that affect the risk of developing fibromyalgia. Many of the genes implicated in these regions are involved in brain and nerve function.
Professor Frances Williams, co-senior author of the paper and professor of genomic epidemiology at King’s College London, played an important role in bringing together the data from 11 health research studies from the US, UK, Finland, Estonia, Denmark, and Iceland, as well as 53 researchers across seven countries.
Dr. Michael Wainberg, an investigator at the Lunenfeld-Tanenbaum Research Institute and the University of Toronto, and co-senior author of the paper, said, “This work changes how we think about fibromyalgia at a fundamental level. For decades, patients have been dismissed or told their pain is simply psychological. Our findings confirm the condition has a clear biological basis.”
While the findings do not yet provide a genetic test for diagnosing fibromyalgia or a new treatment for patients, they offer valuable insights into the underlying biology of the condition. This could help researchers develop better ways to identify, understand, and treat fibromyalgia in the future.
A Surprising Link to Huntington’s Disease
Of the 26 genetic variants identified, the one most strongly linked to fibromyalgia risk was within the HTT gene. Different mutations in this gene cause Huntington’s disease, a severe, progressive, and fatal neurodegenerative disorder. Another variant pointed to a receptor called GPR52 that regulates HTT levels. This receptor is already being investigated as a possible drug target in Huntington’s disease.
Professor Frances Williams helped to interpret how the genetic findings relate to the symptoms and conditions doctors commonly see in patients. The study revealed substantial genetic overlap between fibromyalgia and a range of other conditions, including low back pain, irritable bowel syndrome, and post-traumatic stress disorder. The researchers think that shared biological mechanisms within the nervous system may make people susceptible to several of these conditions, explaining why they often appear together.
Professor Frances Williams said, “We know that chronic pain syndromes cluster together in individuals and families and are genetically similar. Targeting the shared mechanisms underlying them could potentially benefit a whole cluster of disorders.”
Genetics is not the only determinant of whether someone develops fibromyalgia. The authors suspect that even people carrying many genetic variants for fibromyalgia require other risk factors, such as a painful arthritic condition, to trigger fibromyalgia syndrome.
Dr. Nasa Sinnott-Armstrong, assistant professor at Fred Hutch Cancer Center and co-senior author of the paper, said, “Understanding how genes, environmental exposures, and life events jointly contribute to the risk of fibromyalgia syndrome is critical. Further research into triggers of fibromyalgia and corresponding changes in neural tissues will help us understand what drives fibromyalgia and how to treat it.”
The study’s researchers have founded the Chronic Pain Genomics Consortium to investigate other chronic pain syndromes, starting with pelvic pain. The consortium sees fibromyalgia as only the beginning of a broader exploration of the landscape of chronic pain conditions.
Professor Frances Williams said, “This study provides important new insights into why some people develop fibromyalgia syndrome and identifies biological pathways that could lead to new treatment approaches. One of these pathways is already the focus of drug trials for Huntington’s disease, raising the possibility that existing pharmaceutical research could eventually benefit people with fibromyalgia. The findings also help us better understand why fibromyalgia so often occurs alongside conditions such as anxiety and depression, bringing us closer to understanding the condition as a whole.”
Published in journal: Nature Medicine
Title: The genetic architecture of fibromyalgia across 2.5 million individuals
Authors: Isabel Kerrebijn, Gyda Bjornsdottir, Keon Arbabi, Lea Urpa, Hele Haapaniemi, Gudmar Thorleifsson, Lilja Stefansdottir, Stephan Frangakis, Jesse Valliere, Lovemore Kunorozva, Erik Abner, Caleb Ji, Markus Kangur, Bitten Aagaard, Henning Bliddal, Søren Brunak, Mie T. Bruun, Maria Didriksen, Christian Erikstrup, Sarah Finer, Arni J. Geirsson, Daniel F. Gudbjartsson, Thomas F. Hansen, David van Heel, Ingileif Jonsdottir, Stacey Knight, Kirk U. Knowlton, Christina Mikkelsen, Lincoln D. Nadauld, Thorunn A. Olafsdottir, Sisse R. Ostrowski, Ole B. V. Pedersen, Saedis Saevarsdottir, Astros T. Skuladottir, Erik Sørensen, Hreinn Stefansson, Patrick Sulem, Olafur A. Sveinsson, Gudny E. Thorlacius, Unnur Thorsteinsdottir, Henrik Ullum, Arnor Vikingsson, Thomas M. Werge, Chronic Pain Genomics Consortium, FinnGen, DBDS Genomic Consortium, Estonian Biobank Research Team, Genes & Health Research Team, Richa Saxena, Kari Stefansson, Chad M. Brummett, Bente Glintborg, Daniel J. Clauw, Thorgeir E. Thorgeirsson, Frances M. K. Williams, Nasa Sinnott-Armstrong, Hanna M. Ollila, and Michael Wainberg
Source/Credit: King’s College London
Edited by: Scientific Frontline
Reference Number: geno072826_01
.jpg)